Cure8 research brief
The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point to new therapeutic targets to test.
Researchers, translational scientists, clinicians treating biologic-experienced UC patients, and patients on or switching from anti‑TNF therapies
The study analyzed baseline colonic transcriptomes from patients in the UNIFI phase III programme and used network inference, connectivity mapping, ex vivo pharmacology, and spatial transcriptomics to localize signals to stromal niches.
The authors highlight increased extracellular matrix and collagen remodelling, higher stromal cell representation, and inferred MAPK/EGFR activity in patients with prior anti‑TNF failure.
MEK/EGFR inhibitors emerged as candidate perturbagens in computational mapping and MEK inhibition reduced the inferred MAPK/EGFR activity and stromal pathways in ex vivo experiments. The work is presented as a mechanistic, hypothesis‑generating study rather than a clinical trial of a therapy.
Results come from integrative transcriptomic and spatial analyses and ex vivo perturbation experiments; this is hypothesis-generating preclinical research posted as a preprint and not evidence that MEK/EGFR inhibitors are safe or effective for UC.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
